Pipeline/Programs

We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline.

TRN

Candidate & Indication

Discovery

IND-enabling

Phase 1

Phase 2

Phase 3

HOX/MEIS

HOX/
MEIS

Lanraplenib
(SYK Inhibitor)

MYC

Target #1
(PPI Modulator)

AR

Target #2
(Cofactor Modulator)

Undis-closed

Discovery Collaboration

Genentech

Additional proprietary programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs

We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.